Drug Profile
Iberdomide - Bristol Myers Squibb
Alternative Names: BMS-986382; CC-220; IBER; Iberdomide hydrochlorideLatest Information Update: 21 Mar 2024
Price :
$50
*
At a glance
- Originator Celgene Corporation
- Developer Bristol-Myers Squibb; Celgene Corporation; Hackensack Meridian Health
- Class Anti-inflammatories; Antineoplastics; Isoindoles; Piperidones; Skin disorder therapies; Small molecules
- Mechanism of Action Ubiquitin protein ligase complex modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Multiple myeloma
- Phase II Atopic dermatitis; Systemic lupus erythematosus
- Phase I B-cell lymphoma; Follicular lymphoma; Renal failure
- No development reported Non-Hodgkin's lymphoma
- Discontinued Cutaneous lupus erythematosus; Haematological malignancies; Sarcoidosis; Systemic scleroderma
Most Recent Events
- 12 Mar 2024 Hackensack Meridian Health suspends a Phase-I/II clinical trials in Multiple myeloma (Combination therapy, First-line therapy) in USA (PO) due to serious adverse event which is under review (NCT05199311)
- 20 Feb 2024 Pfizer initiates the phase I MagnetisMM-4 trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Canada (PO) (NCT06215118)
- 25 Jan 2024 Bristol-Myers Squibb plans a phase III trial in Multiple myeloma (Combination therapy) in Germany (PO) (NCT06216158)